

**Unaudited Financial Results (Provisional) for the Quarter
& Nine Months ended 31st December, 2007**

(Rs. in Lac)

Sl. No.	Particulars	For Quarter ended		For Nine Months ended		Year ended
		31.12.2007 (Unaudited)	31.12.2006 (Unaudited)	31.12.2007 (Unaudited)	31.12.2006 (Unaudited)	31.03.2007 (Audited)
1	Net Turnover / Income from Operations	22,635	19,712	63,492	60,478	83,155
2	Other Income	62	407	1,810	2,974	2,996
3	Total Income	22,697	20,119	65,302	63,452	86,151
4	Expenditure					
	a) (Increase) / Decrease in stocks in trade and work in progress	2,432	(580)	73	(298)	1,176
	b) Consumption of Materials	7,448	10,432	26,860	27,407	36,417
	c) Purchase of traded goods	380	313	1,451	726	1,002
	d) Manufacturing & Administrative Expenses	1,819	1,429	4,966	4,217	6,264
	e) Employees cost	2,058	1,628	5,728	4,607	7,880
	f) Depreciation	1,120	917	3,039	2,481	3,552
	g) Other expenditure	2,600	2,020	6,511	5,074	7,428
	h) Total	17,857	16,159	48,628	44,214	63,719
5	Interest	472	112	783	1,192	1,522
6	Exceptional Items	-	-	-	-	-
7	Profit from Ordinary Activities before Tax (3-4h-5-6)	4,368	3,848	15,891	18,046	20,910
8	Tax Expenses	1,475	1,138	5,066	5,707	6,229
9	Net Profit from Ordinary Activities after Tax (7-8)	2,893	2,710	10,825	12,339	14,681
10	Extraordinary items (net of tax expense)	-	-	-	-	-
11	Net Profit for the period (9-10)	2,893	2,710	10,825	12,339	14,681
12	Paid-up Equity Share Capital (Face Value Re.1/- per Share)	668	658	668	658	658
13	Reserves excluding Revaluation Reserves	-	-	-	-	53,251
14	Earning Per Share (EPS) (Rs.)					
	- Basic (not annualised)	4.39	4.50	16.42	20.38	23.71
	- Diluted (not annualised)	4.11	4.11	15.36	18.64	21.73
15	Public Shareholding					
	Number of Shares	23,223,770	22,204,164	23,223,770	22,204,164	22,207,664
	Percentage of shareholding	34.74	33.73	34.74	33.73	33.73
Unaudited Segment wise Revenue, Results and Capital employed						
Sl. No.	Particulars	For Quarter ended		For Nine Months ended		Year ended
		31.12.2007 (Unaudited)	31.12.2006 (Unaudited)	31.12.2007 (Unaudited)	31.12.2006 (Unaudited)	31.03.2007 (Audited)
1	Segment Revenue					
	a) Vaccines	17,742	15,092	48,623	47,506	66,387
	b) Formulations	4,984	4,812	15,065	13,228	17,002
	c) Research & Development	4	-	39	53	78
	d) Unallocated	-	-	-	-	-
	Gross Sales/ Income from Operations	22,730	19,904	63,727	60,787	83,467
	Less : Inter Segment Revenue	-	-	-	-	-
	Net Sales/ Income from Operations	22,730	19,904	63,727	60,787	83,467
2	Segment Results (Profit before tax and interest)					
	a) Vaccines	7,345	5,914	21,059	21,332	28,285
	b) Formulations	574	525	2,015	2,161	2,849
	c) Research & Development	(1,279)	(1,431)	(3,715)	(3,634)	(4,972)
	d) Unallocated	-	-	-	-	-
	Total	6,640	5,008	19,359	19,859	26,162
	Less : Interest	472	112	783	1,192	1,522
	Unallocated Expenditure net of unallocated Income	1,800	1,048	2,685	621	3,730
	Total Profit Before Tax	4,368	3,848	15,891	18,046	20,910
3	Capital Employed (Segment Assets - Segments Liabilities)					
	a) Vaccines	48,795	24,635	48,795	24,635	29,930
	b) Formulations	16,242	21,435	16,242	21,435	15,100
	c) Research & Development	15,180	9,400	15,180	9,400	11,257
	d) Unallocated	(11,863)	(3,053)	(11,863)	(3,053)	(2,377)
	Total Capital employed	68,354	52,417	68,354	52,417	53,910

Notes:

- The above financial results were reviewed by the Audit Committee of the Board and approved by the Board of Directors at their meetings held on 23rd January, 2008 & 24th January, 2008, respectively.
 - Tax expenses include provision for income tax, wealth tax, fringe benefit tax and deferred tax liability.
 - The Company has been successfully pre-qualified by WHO for two of its innovative combination vaccines for pediatric immunization - EasyFour (DTP + Hib) and Ecovac (DTP + Hep B).
 - During the quarter, the Company has entered into an MOU with Punjab University, Chandigarh for research collaboration to identify a lead molecule with an aim to bring a drug superior to existing marketed products in the therapeutic area of Psychiatric Disorders.
 - During the quarter, Heber Biotec S.A. Cuba had exit from the joint venture Company Panheber Biotec Pvt. Ltd. due to strategic reasons and their stake therein was bought by the promoter-directors of the Company. The Company has now decided to acquire those shares so as to make it as its Wholly-owned Subsidiary Company.
 - During the quarter, the Company has invested an amount of Rs.400 Lac so as to form a partnership firm with 40% stake therein, with the main object of investment/ purchase of land, stocks, etc.
 - As regards the Auditors' observation in their report on the Audited Accounts for the Financial Year 2006-07 :
With regard to furnishing of information in respect of its suppliers which may fall under "The Micro, Small and Medium Enterprises Development Act, 2006", which was promulgated in October 2006, the Company has already initiated the process of identification of such suppliers. The Company has sent letters to all its suppliers requesting them to furnish necessary details to ascertain their status under the Act so as to enable it to comply with the disclosure requirements under the said Act. The information in respect of suppliers who have furnished the desired details, is being compiled to ascertain the interest liability, if any, under the Act. However, the Company is of the opinion that liability of interest on overdue payments, if any, to such suppliers will not be material.
ii) With regard to non-provision of proportionate premium on redemption of US\$ 50 million Zero Coupon Convertible Bonds due 2011, the management is of the opinion that the bonds are redeemable only if there is no conversion of bonds earlier, the likelihood of which cannot be ascertained presently. Hence the payment of premium on redemption is contingent in nature, the outcome of which is dependent upon uncertain future events. Therefore same was disclosed as a contingent liability in Annual Accounts. Likewise, the proportionate premium on said Bonds amounting to Rs.299 Lac and Rs.879 Lac during quarter and nine months respectively ended 31st December, 2007 has also not been provided.
iii) With regard to capitalization of expenditure on clinical trials amounting to Rs.916 Lac during FY 2006-07 for the purpose of registration of Company's product in US and / or Europe, the management believes that these products would be commercially viable and there is no reason to believe that there is any uncertainty that may lead to not securing registration for the products from the regulatory authorities. An amount of Rs.730 Lac and Rs.1,606 Lac towards above said expenditure on clinical trials during quarter and nine months respectively ended 31st December, 2007 has also been capitalised on similar grounds.
 - The issued Equity Share Capital has increased due to allotment of 987,554 Equity Shares of Re.1/- each at a premium of Rs.356.57 per share upon conversion of 80 Tranche 2 Zero Coupon Foreign Currency Convertible Bonds (FCCBs), on 31.10.2007.
 - Status of Investors' complaints [in nos.] during the quarter, pursuant to clause 41 of listing agreement: Opening [0]; Received [2]; Disposed [2]; Closing [0].
 - The CEO and CFO Certificate in respect of the above results in terms of the requirement of clause 41 of the Listing Agreement, has been placed before the Board of Directors.
 - The previous period's figures have been regrouped/ rearranged/ reclassified wherever necessary.
- Limited Review:** The Statutory Auditors have carried out limited review of the unaudited Financial Results of the Company for the quarter & nine months ended 31st December, 2007 and the related report is being forwarded to the concerned Stock Exchanges. This Report does not have any impact on the above Results and Notes which need to be explained.

New Delhi
January 24, 2008

For and on behalf of the Board
Soshil Kumar Jain
Chairman

Panacea Biotec Ltd.
Regd. Office : Ambala-Chandigarh Highway, Lailu- 140501, Punjab
Website : <http://www.panacea-biotec.com>